Companies
/Healthcare
Supernus Pharmaceuticals Inc
$41.64
▼ $0.05 (−0.12%) today
Markets closed · 4:51pm ET
Today · % change
Fundamentals
Market Cap
$2.4B
Profit Margin
-13.2%
Revenue (TTM)
$830.4M
EPS (TTM)
$-1.92
52-Week Range
$41 – $60
Street Target
$61.75
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and marketing treatments for central nervous system (CNS) diseases. Its portfolio includes Trokendi XR and Oxtellar XR for epilepsy and migraine prevention, Qelbree for ADHD, and several products for Parkinson's Disease such as APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. Additionally, Supernus is advancing research with candidates like SPN-830 for Parkinson's off episodes and SPN-817 for epilepsy. Founded in 2005 and based in Rockville, Maryland, Supernus aims to improve patient care in CNS disorders through innovative therapies.